Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancer

• Published in: Journal of experimental & clinical cancer research Vol. 44; no. 1; pp. 174 - 17
• Main Authors: Ben Sassi, Mehdi, Azais, Henri, Marcaillou, Charles, Guibert, Sylvain, Martin, Emmanuel, Alexandre, Jérôme, Benoit, Louise, de Reynies, Aurélien, Laude, Emilie, Duong, Cam, Medioni, Jacques, Borghese, Bruno, Bats, Anne-Sophie, Taly, Valerie, Laurent-Puig, Pierre
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.06.2025; BioMed Central; BMC
• Subjects: Adult; Aged; Biomarkers, Tumor - genetics; Cancer therapies; Carcinoma, Ovarian Epithelial - blood; Carcinoma, Ovarian Epithelial - diagnosis; Carcinoma, Ovarian Epithelial - genetics; Carcinoma, Ovarian Epithelial - pathology; Chemotherapy; Circulating Tumor DNA - blood; Circulating Tumor DNA - genetics; Design; DNA Methylation; Epigenetics; Exome Sequencing; Female; Health aspects; Humans; Methylation; Middle Aged; Mortality; Mutation; Neoplasm, Residual - genetics; Ovarian cancer; Ovarian Neoplasms - blood; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Patients; Plasma; Surgery; Tumors; Whole genome sequencing

Epithelial ovarian cancer (EOC) is a leading cause of cancer mortality in women, often diagnosed at advanced stages. While first-line treatments improve survival, relapses remain common, with 5-year survival rates below 40%. Circulating tumor DNA (ctDNA) is a promising biomarker for non-invasive EOC...